SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2989-2998. Prepublished online as a Blood First Edition Paper on December 5, 2006; DOI 10.1182/blood-2006-10-051110. This Article Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2006-10-051110v1 109/7/2989    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bomben, R. Articles by Gattei, V. Search for Related Content PubMed PubMed Citation Articles by Bomben, R. Articles by Gattei, V. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 6, 2006 Accepted November 22, 2006 Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study Riccardo Bomben, Michele Dal Bo, Daniela Capello, Dania Benedetti, Daniela Marconi, Antonella Zucchetto, Francesco Forconi, Rossana Maffei, Emanuela M Ghia, Luca Laurenti, Pietro Bulian, Maria Ilaria Del Principe, Giuseppe Palermo, Mia Thorselius, Massimo Degan, Renato Campanini, Anna Guarini, Giovanni Del Poeta, Richard Rosenquist, Dimitar G Efremov, Roberto Marasca, Robin Foa, Gianluca Gaidano, and Valter Gattei* Clinical & Experimental Hematology Research Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy Dept of Physics, University of Bologna, Bologna, Italy Dept of Clinical Medicine & Immunological Sciences, University of Siena, Siena, Italy Division of Hematology, Dept of Oncology & Hematology, University of Modena and Reggio Emilia, Modena, Italy Dept of Cellular Biotechnologies & Hematology, University, Rome, Italy Hematology Institute, Catholic University, Rome, Italy Chair of Hematology, S.Eugenio Hospital and University of Tor Vergata, Rome, Italy Dept of Genetics & Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden ICGEB Outstation-Monterontondo, CNR Campus, Rome, Italy * Corresponding author; email: vgattei{at}cro.it. IGHV3-21-using chronic lymphocytic leukemia (CLL) is a distinct entity with restricted immunoglobulin gene features and poor prognosis, more frequently encountered in Northern than Southern Europe. To further investigate this subset and its geographical distribution in the context of a country (Italy) with both continental and Mediterranean areas, 37 IGHV3-21 CLLs were collected out of 1076 cases enrolled by different Institutions from Northern or Central-Southern Italy. 18/37 cases, identified as homologous(hom)HCDR3-IGHV3-21 CLLs, were found almost exclusively (16/18) in Northern Italy, while 19 non-homHCDR3-IGHV3-21 cases were similarly distributed throughout Italy. Clinically, poor survivals were documented for IGHV3-21 CLLs as well as for subgroups of mutated and homHCDR3-IGHV3-21 CLLs. Negative prognosticators CD38, ZAP-70, CD49d, CD79b were expressed at higher levels in homHCDR3 than non-homHCDR3-IGHV3-21 cases. Differential gene expression profiling (GEP) of 13 IGHV3-21 vs. 52 non-IGHV3-21 CLLs, identified, among 122 best-correlated genes, TGFB2 and VIPR1 as down- and up-regulated in IGHV3-21 CLL cases, respectively. Moreover, GEP of 7 homHCDR3 vs. 6 non-homHCDR3-IGHV3-21 CLLs yielded 20 differentially expressed genes, WNT16 being that expressed at the highest levels in homHCDR3-IGHV3-21 CLLs. Altogether, IGHV3-21 CLLs, including those with homHCDR3, had a peculiar global phenotype in part explaining their worse clinical outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Rossi, V. Spina, M. Cerri, S. Rasi, C. Deambrogi, L. De Paoli, L. Laurenti, R. Maffei, F. Forconi, F. Bertoni, et al. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome Clin. Cancer Res., July 1, 2009; 15(13): 4415 - 4422. [Abstract] [Full Text] [PDF] A. Zucchetto, D. Benedetti, C. Tripodo, R. Bomben, M. Dal Bo, D. Marconi, F. Bossi, D. Lorenzon, M. Degan, F. M. Rossi, et al. CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival Cancer Res., May 1, 2009; 69(9): 4001 - 4009. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] E. M. Ghia, S. Jain, G. F. Widhopf II, L. Z. Rassenti, M. J. Keating, W. G. Wierda, J. G. Gribben, J. R. Brown, K. R. Rai, J. C. Byrd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection Blood, May 15, 2008; 111(10): 5101 - 5108. [Abstract] [Full Text] [PDF] F. Forconi, E. Sozzi, D. Rossi, S. S. Sahota, T. Amato, D. Raspadori, L. Trentin, L. Leoncini, G. Gaidano, and F. Lauria Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia Haematologica, May 1, 2008; 93(5): 697 - 705. [Abstract] [Full Text] [PDF] V. Gattei, P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia Blood, January 15, 2008; 111(2): 865 - 873. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020